Growth factor messenger RNA expression by human breast fibroblasts from benign and malignant lesions

Kevin J. Cullen, Helene S. Smith, Suzanne Hill, Marc E Lippman, Marc E. Lippman

Research output: Contribution to journalArticle

188 Citations (Scopus)

Abstract

Breast tumors are a complex mix of epithelial, stromal, and vascular elements. We examined primary cultures of breast fibroblasts derived from benign and malignant lesions for expression of various growth factors. All fibroblast cultures, regardless of whether they were derived from benign or malignant lesions, expressed platelet-derived growth factor A chain, basic fibroblast growth factor, fibroblast growth factor 5, and transforming growth factor β1 mRNA. None expressed platelet-derived growth factor B chain or transforming growth factor α mRNA. However, examination of mRNA expression for the insulin-like growth factors revealed that 7 of 8 fibroblasts derived from benign lesions expressed insulin-like growth factor I (IGF-I) mRNA, while only 1 of 9 fibroblasts derived from malignancies expressed IGF-I mRNA. The opposite picture was seen for insulin-like growth factor II (IGF-II) mRNA expression, in which 1 of 9 benign-derived fibroblasts expressed IGF-II mRNA, while 5 of 9 malignant-derived fibroblasts expressed IGF-II. This correlated with previous in situ hybridization data, which showed IGF-I mRNA expression confined to the stroma of benign breast tissue. PDGF treatment of tumor fibroblasts resulted in a 3-fold increase in IGF-II mRNA. Thus there was an apparent dichotomy between IGF-I mRNA expression in the majority of fibroblasts derived from benign lesions and IGF-II mRNA expression in the majority of tumor-derived fibroblasts. Since the insulin-like growth factors are potent mitogens for breast tumor epithelial cells, this further supports the notion of a paracrine growth-promoting role for the insulin-like growth factors in breast lesions and suggests that IGF-II may be the more important growth promoter in malignant lesions.

Original languageEnglish
Pages (from-to)4978-4985
Number of pages8
JournalCancer Research
Volume51
Issue number18
StatePublished - Sep 15 1991
Externally publishedYes

Fingerprint

Intercellular Signaling Peptides and Proteins
Breast
Fibroblasts
Insulin-Like Growth Factor II
Messenger RNA
Insulin-Like Growth Factor I
Somatomedins
Transforming Growth Factors
Fibroblast Growth Factor 5
Proto-Oncogene Proteins c-sis
Breast Neoplasms
Neoplasms
Fibroblast Growth Factor 2
Growth
Mitogens
In Situ Hybridization
Blood Vessels
Epithelial Cells

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cullen, K. J., Smith, H. S., Hill, S., Lippman, M. E., & Lippman, M. E. (1991). Growth factor messenger RNA expression by human breast fibroblasts from benign and malignant lesions. Cancer Research, 51(18), 4978-4985.

Growth factor messenger RNA expression by human breast fibroblasts from benign and malignant lesions. / Cullen, Kevin J.; Smith, Helene S.; Hill, Suzanne; Lippman, Marc E; Lippman, Marc E.

In: Cancer Research, Vol. 51, No. 18, 15.09.1991, p. 4978-4985.

Research output: Contribution to journalArticle

Cullen, KJ, Smith, HS, Hill, S, Lippman, ME & Lippman, ME 1991, 'Growth factor messenger RNA expression by human breast fibroblasts from benign and malignant lesions', Cancer Research, vol. 51, no. 18, pp. 4978-4985.
Cullen KJ, Smith HS, Hill S, Lippman ME, Lippman ME. Growth factor messenger RNA expression by human breast fibroblasts from benign and malignant lesions. Cancer Research. 1991 Sep 15;51(18):4978-4985.
Cullen, Kevin J. ; Smith, Helene S. ; Hill, Suzanne ; Lippman, Marc E ; Lippman, Marc E. / Growth factor messenger RNA expression by human breast fibroblasts from benign and malignant lesions. In: Cancer Research. 1991 ; Vol. 51, No. 18. pp. 4978-4985.
@article{02a226b44cce444886f25ab3290f20ac,
title = "Growth factor messenger RNA expression by human breast fibroblasts from benign and malignant lesions",
abstract = "Breast tumors are a complex mix of epithelial, stromal, and vascular elements. We examined primary cultures of breast fibroblasts derived from benign and malignant lesions for expression of various growth factors. All fibroblast cultures, regardless of whether they were derived from benign or malignant lesions, expressed platelet-derived growth factor A chain, basic fibroblast growth factor, fibroblast growth factor 5, and transforming growth factor β1 mRNA. None expressed platelet-derived growth factor B chain or transforming growth factor α mRNA. However, examination of mRNA expression for the insulin-like growth factors revealed that 7 of 8 fibroblasts derived from benign lesions expressed insulin-like growth factor I (IGF-I) mRNA, while only 1 of 9 fibroblasts derived from malignancies expressed IGF-I mRNA. The opposite picture was seen for insulin-like growth factor II (IGF-II) mRNA expression, in which 1 of 9 benign-derived fibroblasts expressed IGF-II mRNA, while 5 of 9 malignant-derived fibroblasts expressed IGF-II. This correlated with previous in situ hybridization data, which showed IGF-I mRNA expression confined to the stroma of benign breast tissue. PDGF treatment of tumor fibroblasts resulted in a 3-fold increase in IGF-II mRNA. Thus there was an apparent dichotomy between IGF-I mRNA expression in the majority of fibroblasts derived from benign lesions and IGF-II mRNA expression in the majority of tumor-derived fibroblasts. Since the insulin-like growth factors are potent mitogens for breast tumor epithelial cells, this further supports the notion of a paracrine growth-promoting role for the insulin-like growth factors in breast lesions and suggests that IGF-II may be the more important growth promoter in malignant lesions.",
author = "Cullen, {Kevin J.} and Smith, {Helene S.} and Suzanne Hill and Lippman, {Marc E} and Lippman, {Marc E.}",
year = "1991",
month = "9",
day = "15",
language = "English",
volume = "51",
pages = "4978--4985",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "18",

}

TY - JOUR

T1 - Growth factor messenger RNA expression by human breast fibroblasts from benign and malignant lesions

AU - Cullen, Kevin J.

AU - Smith, Helene S.

AU - Hill, Suzanne

AU - Lippman, Marc E

AU - Lippman, Marc E.

PY - 1991/9/15

Y1 - 1991/9/15

N2 - Breast tumors are a complex mix of epithelial, stromal, and vascular elements. We examined primary cultures of breast fibroblasts derived from benign and malignant lesions for expression of various growth factors. All fibroblast cultures, regardless of whether they were derived from benign or malignant lesions, expressed platelet-derived growth factor A chain, basic fibroblast growth factor, fibroblast growth factor 5, and transforming growth factor β1 mRNA. None expressed platelet-derived growth factor B chain or transforming growth factor α mRNA. However, examination of mRNA expression for the insulin-like growth factors revealed that 7 of 8 fibroblasts derived from benign lesions expressed insulin-like growth factor I (IGF-I) mRNA, while only 1 of 9 fibroblasts derived from malignancies expressed IGF-I mRNA. The opposite picture was seen for insulin-like growth factor II (IGF-II) mRNA expression, in which 1 of 9 benign-derived fibroblasts expressed IGF-II mRNA, while 5 of 9 malignant-derived fibroblasts expressed IGF-II. This correlated with previous in situ hybridization data, which showed IGF-I mRNA expression confined to the stroma of benign breast tissue. PDGF treatment of tumor fibroblasts resulted in a 3-fold increase in IGF-II mRNA. Thus there was an apparent dichotomy between IGF-I mRNA expression in the majority of fibroblasts derived from benign lesions and IGF-II mRNA expression in the majority of tumor-derived fibroblasts. Since the insulin-like growth factors are potent mitogens for breast tumor epithelial cells, this further supports the notion of a paracrine growth-promoting role for the insulin-like growth factors in breast lesions and suggests that IGF-II may be the more important growth promoter in malignant lesions.

AB - Breast tumors are a complex mix of epithelial, stromal, and vascular elements. We examined primary cultures of breast fibroblasts derived from benign and malignant lesions for expression of various growth factors. All fibroblast cultures, regardless of whether they were derived from benign or malignant lesions, expressed platelet-derived growth factor A chain, basic fibroblast growth factor, fibroblast growth factor 5, and transforming growth factor β1 mRNA. None expressed platelet-derived growth factor B chain or transforming growth factor α mRNA. However, examination of mRNA expression for the insulin-like growth factors revealed that 7 of 8 fibroblasts derived from benign lesions expressed insulin-like growth factor I (IGF-I) mRNA, while only 1 of 9 fibroblasts derived from malignancies expressed IGF-I mRNA. The opposite picture was seen for insulin-like growth factor II (IGF-II) mRNA expression, in which 1 of 9 benign-derived fibroblasts expressed IGF-II mRNA, while 5 of 9 malignant-derived fibroblasts expressed IGF-II. This correlated with previous in situ hybridization data, which showed IGF-I mRNA expression confined to the stroma of benign breast tissue. PDGF treatment of tumor fibroblasts resulted in a 3-fold increase in IGF-II mRNA. Thus there was an apparent dichotomy between IGF-I mRNA expression in the majority of fibroblasts derived from benign lesions and IGF-II mRNA expression in the majority of tumor-derived fibroblasts. Since the insulin-like growth factors are potent mitogens for breast tumor epithelial cells, this further supports the notion of a paracrine growth-promoting role for the insulin-like growth factors in breast lesions and suggests that IGF-II may be the more important growth promoter in malignant lesions.

UR - http://www.scopus.com/inward/record.url?scp=0026425624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026425624&partnerID=8YFLogxK

M3 - Article

C2 - 1893385

AN - SCOPUS:0026425624

VL - 51

SP - 4978

EP - 4985

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 18

ER -